I feel like in most other fields you would just focus on the the soluble MPMP modeling and become a provider to antibody companies, who would in turn sell their candidates off to a company specialized in pushing through clinical trials and approval. But instead it seems like biotech startups try to own the entire chain, as if they were J&J. Is that the case, and if so why do you think it is? Is biotech still too new and niche?
I will start by thanking Abhishaike Mahajan for his insightful article. I am pretty new to this, but I think this trying to own the entire chain in this case may be due to patenting issues ( actual reduction to practice and so on). But that's just a hunch on my part, and I am curious to know the answer to this one myself.
wouldn't there be an issue when trying to analyze their structure if you worked in such condition ? I don't know if you can use an oil/water interface in a cryo-em
I feel like in most other fields you would just focus on the the soluble MPMP modeling and become a provider to antibody companies, who would in turn sell their candidates off to a company specialized in pushing through clinical trials and approval. But instead it seems like biotech startups try to own the entire chain, as if they were J&J. Is that the case, and if so why do you think it is? Is biotech still too new and niche?
I will start by thanking Abhishaike Mahajan for his insightful article. I am pretty new to this, but I think this trying to own the entire chain in this case may be due to patenting issues ( actual reduction to practice and so on). But that's just a hunch on my part, and I am curious to know the answer to this one myself.
The dumb obvious solution is to give these proteins an oil water interface by just using greasy test tubes.
wouldn't there be an issue when trying to analyze their structure if you worked in such condition ? I don't know if you can use an oil/water interface in a cryo-em